Welcome to our dedicated page for CANNABIS BIOSCI INTL HLDG news (Ticker: CBIH), a resource for investors and traders seeking the latest updates and insights on CANNABIS BIOSCI INTL HLDG stock.
Cannabis Bioscience International Holdings (CBIH), based in Houston, Texas, is a pioneering company in the cannabis industry. Led by CEO Dante Picazo, CBIH focuses on cannabinoid research and innovation, aiming to establish industry standards. Recent achievements include appointing Mr. John E. Jones as Treasurer and Director, known for his strategic guidance and fiscal oversight in previous executive roles. CBIH's partnership with StoneBridge Advisory for company valuation and collaboration with Vita Biotech Research for funding clinical data collection trials highlight the company's commitment to cutting-edge research and strategic growth.
Vita Biotech has partnered with Cannabis Bioscience International Holdings (OTC Pink: CBIH) to fund CBIH's clinical studies. This alliance will expedite CBIH's data collection for evaluating their formulations' efficacy and safety, facilitating the company's scientific and commercial objectives. The partnership involves Vita Biotech acting as a financial subsidiary, aiding in streamlined financing, and risk management by isolating each medical formulation into a unique legal entity. Texas has been chosen for patent housing due to its favorable business environment. Both companies maintain ethical standards and prioritize data integrity, aiming to enhance patient care and credibility in medical cannabis research.
Cannabis Bioscience International Holdings (CBIH) has engaged StoneBridge Advisory for a comprehensive company valuation. StoneBridge, a Colorado-based firm with over 30 years of experience, specializes in business valuations and mergers and acquisitions. This valuation aims to enhance strategic decision-making, attract investments, and facilitate negotiations, especially in light of potential U.S. federal reclassification of cannabis.
CBIH anticipates the valuation will help identify growth opportunities and navigate the evolving medical cannabis market. The company is preparing to capitalize on new business partnerships, funding, and banking services stemming from possible legal changes. The valuation is seen as essential for market comparison and long-term sustainability.
Cannabis Bioscience International Holdings (CBIH) has appointed Mr. John E. Jones as its new Treasurer and Director. Mr. Jones brings a wealth of experience from his successful career in the business sector, with a focus on strategic acquisitions, mergers, and capital projects. His expertise is expected to bolster CBIH's position in the cannabis industry, particularly in cannabinoid research and innovation.
FAQ
What is the current stock price of CANNABIS BIOSCI INTL HLDG (CBIH)?
What is the market cap of CANNABIS BIOSCI INTL HLDG (CBIH)?
Who is the CEO of Cannabis Bioscience International Holdings (CBIH)?
What recent achievement did CBIH announce?
What partnerships has CBIH formed recently?
Where is Cannabis Bioscience International Holdings (CBIH) based?
What is the focus of CBIH?
How does CBIH describe its recent collaborations?
Who is Mr. John E. Jones, recently appointed by CBIH?
What is CBIH's strategic focus for the future?
Why is CBIH collaborating with Vita Biotech Research?
How does CBIH approach risk management in its business strategy?